Page 420 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(9) Van Staa T-P, Leufkens HG, Zhang B, Smeeth L. A Comparison of
Cost Effectiveness Using Data from Randomized Trials or Actual Clinical
Practice: Selective Cox-2 Inhibitors as an Example. PLoS Med. 2009 Dec
8;6(12):e1000194.

(10) Safer DJ. Design and reporting modifications in industry-
sponsored comparative psychopharmacology trials. J. Nerv. Ment. Dis.
2002 Sep;190(9):583–92.

(11) Califf RM, DeMets DL. Principles From Clinical Trials Relevant to
Clinical Practice: Part I. Circulation. 2002 Aug 20;106(8):1015–21.

(12) Mueller PS, Montori VM, Bassler D, Koenig BA, Guyatt GH. Ethical
Issues in Stopping Randomized Trials Early Because of Apparent Benefit.
Annals of Internal Medicine. 2007 Jun 19;146(12):878–881.

(13) Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al.
Stopping Randomized Trials Early for Benefit and Estimation of Treatment
Effects: Systematic Review and Meta-regression Analysis. JAMA. 2010 Mar
24;303(12):1180–7.

(14) Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH,
Briel M, et al. Randomized Trials Stopped Early for Benefit: A Systematic
Review. JAMA. 2005 Nov 2;294(17):2203–9.

(15) Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in
oncology: for patients or for industry? Annals of Oncology [Internet]. 2008
Jan 1 [cited 2012 Feb 14]; Available from: http://annonc.oxfordjournals
.org/content/early/2008/04/09/annonc.mdn042.full.

(16) Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART)
study. The Lancet. 2005 Oct;366(9493):1261-2.

(17) Rickard KA. Misleading data analyses in salmeterol (SMART)
study—GlaxoSmithKline’s reply. The Lancet. 2005 Oct;366(9493):1262.

(18) Garcialopez F, Dealvaro F. INSIGHT and NORDIL. The Lancet. 2000
Dec 2;356(9245):1926-1926.

420